none of the six snps of il28b could predict treatment responses in genotype 2 chronic hcv infected patients by propensity score matching analysis没有六个snp的il28b可以预测治疗反应在慢性丙肝病毒感染患者基因型2倾向得分匹配分析.pdfVIP

None of the Six SNPs of IL28B Could Predict Treatment Responses in Genotype 2 Chronic HCV Infected Patients by Propensity Score Matching Analysis 1,4 1,2 2,3 1 1 Wen-Juei Jeng , Chun-Yen Lin , Ji-Yih Chen , Chang-Wen Huang , Chien-Hao Huang , I-Shyan Sheen1,2* 1 Division of Hepatology, Department of Gastroenterology and Hepatology, Linkou Medical Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 2 College of Medicine, Chang Gung University, Taoyuan, Taiwan, 3 Department of Rheumatology, Allergy and Immunology, Linkou Medical Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 4 Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan Abstract Background Aims: A combination of pegylated interferon-alpha and ribavirin (PR) is the standard therapy for patients with chronic hepatitis C. The impact of polymorphism of interleukin-28B (IL28B) on sustained virological response (SVR) to PR has been well documented in patients with CHC genotype-1 (GT1), but it is controversial in genotype-2 (GT2) CHC patients. This study investigated the predictability of six single nucleotide polymorphisms (SNP) of IL28B on the treatment responses of PR in patients with CHC GT2. Method: 197 CHC GT2 consecutive patients who received PR treatment in our prospective cohort were enrolled. Hepatitis C virus (HCV) genotyping, quantification of HCV-RNA and genotyping of the ten SNPs of IL28B were performed. Six SNPs of IL28B were chosen for analysis. The propensity score matching (PSM) analysis was applied using patients with CHC GT1 in another prospective cohort as a positive comparison to avoid covariate bias. Results: The distribution of the six SNPs was similar in GT1 and GT2 patients. Five of these